Product Notifications

Miscellaneous Product Updates

Revised Date: November 22, 2013

  • The recommended dosage for lorazepam (IV bolus) for pediatric patients in the setting of amphetamine overdose is being revised in PoisinDex® Managements, ToxPoints®, Meditext® Managements, and DrugPoints®, and will appear in all platforms by no later than December 16, 2013.

  • The Centers for Disease Control and Prevention (CDC), the National Institutes of Health (NIH), and the HIV Medicine Association (HIVMA) of the Infectious Diseases Society of America (IDSA) have developed guidelines for preventing and treating opportunistic infections (OIs) among individuals infected with human immunodeficiency virus (HIV). Specific recommendations regarding the prevention and treatment of bartonella infection in patients with HIV are provided that address the following: 1) the prevention of exposure to the opportunistic pathogen, 2) prevention of the first episode of the disease, 3) prevention of disease recurrence, 4) when to initiate antiretroviral therapy (ART) in ART-naive patients with opportunistic infection, and 5) treatment of disease, including drug regimens and dosing. These new guidelines will be in our content by no later than December 31st.

  • The FDA has approved the importation and emergency use of a meningococcal group B vaccine that is available in Europe and Australia in response to the eight outbreaks of type B meningitis at Princeton University. Type B meningitis is rare in the US and the current formulation of meningococcal vaccine available in the US does not cover group B. We are providing information on this vaccine in a new Drug Summary document titled Meningococcal Vaccine, Group B. Additionally, you can find information on the meningococcal group B vaccine in the Meningococcal Vaccine Drug Evaluation monograph.

  • Eslicarbazepine (Aptiom®) has been approved by the FDA for the adjunctive treatment of partial-onset seizures, and complete US information on this drug has been added to our products. In clinical trials that involved more than 1400 patients, eslicarbazepine lowered seizure frequency by more than 50% in 41% of treated patients. Eslicarbazepine is already approved for use in Europe.

  • The FDA has asked drug manufacturer Ariad Pharmaceuticals to suspend the sales and marketing of their leukemia drug, ponatinib (Iclusig™), due to questions around the drug's safety. Patients in clinical trials have exhibited an increased rate of thrombotic events and narrowing of the blood vessels, which have led to myocardial infarction, stroke, and death. The drug is currently available only under an expanded access registry program while the FDA continues to investigate. We have left information on ponatinib in our products and you can still access it in Micromedex, even though the content has been updated to reflect this recall.

  • Zohydro™ ER, the first oral single-entity formulation of hydrocodone, is now available in the US for pain management in patients who need around-the-clock pain control. It is the first opioid approved under the new FDA requirements for postmarketing studies and prescribing information with stronger warnings and clearer guidelines for appropriate use. The box warning includes information on addiction, abuse, and misuse; respiratory depression; accidental exposure; neonatal opioid withdrawal syndrome; and interaction with alcohol. It is a Schedule II controlled substance. We have created information on Zohydro™ ER as both a Drug Summary document and a Drug Evaluation document. 
International Mobile Drug Info App - ITunes

Revised Date: October 23, 2013

Welcome to Micromedex Drug Information App Support
Please note that this page is for app users outside the US & Canada only. If you are a US or Canadian user, please go to the ITunes store for download information.

Are you looking for the latest update to the free Micromedex Drug Information app?
Micromedex apps are not available for individual purchase outside the US and Canada. Beginning 31 October 2013 this app is free for Micromedex subscribers only.

Micromedex subscribers continue to enjoy free access to the Drug Information app, as well as four additional apps (Drug Interactions, IV Compatibility, Neofax Essentials, and Pediatric Essentials), which are available via iTunes.

For information on how to become a Micromedex customer, please contact micromedex@truvenhealth.com.

If you believe you work for, or are a student of, an organization that has access to Micromedex products, please CLICK HERE to contact our Customer Resource Center for help finding your new app password. Please provide us with as much information as possible, to help us provide the access you are entitled.

 

New URL and Data Center Migration Plans for Micromedex Solutions
Revised Date: May 30, 2013

It is an exciting time for Truven Health Analytics and our partnership with you, our valued customers. As we are establishing ourselves as a new company we have entered into a strategic partnership with Savvis Business for world-class data center and hosting services.

We are conducting detailed planning in conjunction with Thomson Reuters, our previous owner, and other strategic partners, and will soon be migrating all of our services and products to our new data center facilities.

For you, this will mean the following changes:

  • Effective February 27, 2013: a new URL/ Internet domain address for Micromedex 2.0, CareNotes, Formulary, RED BOOK, and NeoFax/ Peds will take effect.
  • This change impacts all access methods including:
    • Bookmarks to web based products
    • InfoButton, links/bookmarks from your HIS system
    • Deep Linking, and
    • Trusted Source [referring URL] authentication customers

  • Brief site outage: As we migrate to our new data center, customers will experience a brief site outage for approximately 30 minutes. The outage will occur during our lowest usage period to minimize customer impact. In addition, administrative tools (Healthcare Series Administration, CareNotes Administration, and Formulary Administration) will be unavailable until Monday 8AM MST.
  • For customers who limit internet access using Firewall Access Control Lists, our new IP will be 157.199.115.130 beginning June 15th.

 

iOS Device Compatibility Update
Revised Date: April 12, 2013

The next release (May 2013) of the Truven Health Analytics, Micromedex Solutions mobile applicaitons will support iOS devices with Retina display and support the 4-inch display on iPhone 5.

All apps, including the Truven Health Analytics, Micromedex Solutions mobile applications, on the app store will no longer be supported for iPhone 3G and lower devices.

iPhone 3GS and higher will be supported, and your experience on these devices should be unaffected.

For additional details, including a matrix listing product compatibility, download the following document. http://micromedex.com/support/downloads/?file_ID=121

For further assistance, please contact Truven Health-Micromedex Support http://support.micromedex.com/support/request/ 

QUICK REFERENCE
Trusted Evidence Mobile Support Resource Center